Literature DB >> 1335545

The role of reactive oxygen species in the pathogenesis of multiple sclerosis.

S M LeVine1.   

Abstract

Although reactive oxygen species are thought to mediate cellular damage in many disease states the role of reactive oxygen species in the pathogenesis of multiple sclerosis is unknown. Data from biochemical, histochemical and pharmacological studies have been evaluated to determine if the necessary conditions exist for the formation of reactive oxygen species during a demyelination episode of multiple sclerosis. This evaluation found that not only do the necessary conditions exist for the formation of reactive oxygen species but that these species may play a significant pathogenic role in this disease. A hypothesis describing a detailed role of reactive oxygen species in the pathogenesis of multiple sclerosis is put forth.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1335545     DOI: 10.1016/0306-9877(92)90121-r

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  22 in total

1.  Patients with multiple sclerosis show increased oxidative stress markers and somatic telomere length shortening.

Authors:  Jing-Zhi Guan; Wei-Ping Guan; Toyoki Maeda; Xie Guoqing; Wan GuangZhi; Naoki Makino
Journal:  Mol Cell Biochem       Date:  2014-11-26       Impact factor: 3.396

Review 2.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.

Authors:  Julien H Park; Christiane Elpers; Janine Reunert; Michael L McCormick; Julia Mohr; Saskia Biskup; Oliver Schwartz; Stephan Rust; Marianne Grüneberg; Anja Seelhöfer; Ulrike Schara; Eugen Boltshauser; Douglas R Spitz; Thorsten Marquardt
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 4.  Exercise and brain health--implications for multiple sclerosis: Part 1--neuronal growth factors.

Authors:  Lesley J White; Vanessa Castellano
Journal:  Sports Med       Date:  2008       Impact factor: 11.136

5.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

6.  Paraoxonase 1 polymorphisms are not related with the risk for multiple sclerosis.

Authors:  Carmen Martínez; Elena García-Martín; Julián Benito-León; Patricia Calleja; María Díaz-Sánchez; Diana Pisa; Hortensia Alonso-Navarro; Lucía Ayuso-Peralta; Dolores Torrecilla; José A G Agúndez; Félix Javier Jiménez-Jiménez
Journal:  Neuromolecular Med       Date:  2009-10-14       Impact factor: 3.843

7.  Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress.

Authors:  Jingdong Qin; Rajendra Goswami; Sylvia Dawson; Glyn Dawson
Journal:  J Neurosci Res       Date:  2008-08-15       Impact factor: 4.164

8.  The Role of Calpain and Proteasomes in the Degradation of Carbonylated Neuronal Cytoskeletal Proteins in Acute Experimental Autoimmune Encephalomyelitis.

Authors:  Suzanne M Smerjac; Jianzheng Zheng; Che-Lin Hu; Oscar A Bizzozero
Journal:  Neurochem Res       Date:  2018-09-24       Impact factor: 3.996

9.  Current Complementary and Alternative Therapies for Multiple Sclerosis.

Authors:  Allen C. Bowling; Thomas M. Stewart
Journal:  Curr Treat Options Neurol       Date:  2003-01       Impact factor: 3.598

Review 10.  Targeting NADPH oxidases for the treatment of cancer and inflammation.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Cell Mol Life Sci       Date:  2012-05-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.